The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue 4, 2013, Pages 480-484

  Bruce, Robert Douglas ^a   Winkle, Peter ^b   Custodio, Joseph M ^c   Wei, Lilian Xuelian ^c   Rhee, Martin S ^c   Kearney, Brian P ^c   Ramanathan, Srinivasan ^c   Friedland, Gerald H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Anaheim Clinical Trials   (United States)

^c GILEAD SCIENCES   (United States)

Author keywords

Buprenorphine naloxone; Cobicistat; Elvitegravir; Pharmacokinetics; Substance abuse

Indexed keywords

BUPRENORPHINE PLUS NALOXONE; COBICISTAT; ELVITEGRAVIR;

ADD ON THERAPY; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG INTERACTION; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIMIT OF QUANTITATION; LONG TERM CARE; MALE; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; OPIATE ADDICTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SERODIAGNOSIS; STEADY STATE;

ADULT; ANTI-RETROVIRAL AGENTS; AREA UNDER CURVE; BUPRENORPHINE; CARBAMATES; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HIV SERONEGATIVITY; HUMANS; MALE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; QUINOLONES; THIAZOLES;

EID: 84880230337     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182961d31     Document Type: Article

References (26)

1. Bruce RD, Altice FL, Friedland GH. HIV Disease among Substance Users:Treatment Issues. In:Volberding P, ed. Global HIV/AIDS Medicine. New York:Elsevier; 2007.
2. Lucas GM, Mullen BA, McCaul ME, et al. Adherence, drug use, and treatment failure in a methadone-clinic-based program of directly administered antiretroviral therapy. AIDS Patient Care STDS. 2007;21:564-574.
3. Kerr T, Wodak A, Elliott R, et al. Opioid substitution and HIV/AIDS treatment and prevention. Lancet. 2004;364:1918-1919.
4. Altice FL, Sullivan LE, Smith-Rohrberg D, et al. The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention. Clin Infect Dis.2006;43 (suppl 4):S178-183.
5. Basu S, Smith-Rohrberg D, Bruce RD, et al. Models for integrating buprenorphine therapy into the primary HIV care setting. Clin Infect Dis. 2006;42:716-721.
6. Altice FL, Bruce RD, Lucas GM, et al. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings:results from a multisite study. J Acquir Immune Defic Syndr. 2011;56(suppl 1):S22-32.
7. Bruce RD, Altice FL. Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir. AIDS. 2006; 20:783-784.
8. Bruce RD, Altice FL, Gourevitch MN, et al. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications:implications and management for clinical practice. J Acquir Immune Defic Syndr. 2006;41:563-572.
9. Bruce RD, McCance-Katz E, Kharasch ED, et al. Pharmacokinetic interactions between buprenorphine and antiretroviral medications. Clin Infect Dis. 2006;43(suppl 4):S216-223.
10. Spire B, Lucas GM, Carrieri MP. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). Int J Drug Policy. 2007;18:262-270.
11. Bruce RD, Altice FL, Moody DE, et al. Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. Drug Alcohol Depend. 2009;105:234-239.
12. Lucas GM, Gebo KA, Chaisson RE, et al. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS. 2002;16:767-774.
13. Altice FL, Friedland GH, Cooney EL. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS. 1999;13:957-962.
14. Bruce RD, Altice FL. Clinical care of the HIV-infected drug user. Infect Dis Clin North Am. 2007;21:149-179, ix.
15. Cone EJ, Gorodetzky CW, Yousefnejad D, et al. The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos. 1984;12:577-581.
16. Chang Y, Moody DE, McCance-Katz EF. Novel metabolites of buprenorphine detected in human liver microsomes and human urine. Drug Metab Dispos. 2006;34:440-448.
17. Elkader A, Sproule B. Buprenorphine:clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet. 2005;44:661-680.
18. Chang Y, Moody DE. Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP-glucuronosyltransferases. Drug Metab Lett. 2009;3:101-107.
19. Rouguieg K, Picard N, Sauvage FL, et al. Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. Drug Metab Dispos. 2010;38:40-45.
20. Ramanathan S, Mathias AA, German P, et al. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet. 2011;50:229-244.
21. Mathias AA, German P, Murray BP, et al. Pharmacokinetics and pharmacodynamics of GS-9350:A novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther. 2010;87:322-329.
22. Handelsman L, Cochrane KJ, Aronson MJ, et al. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse. 1987;13:293-308.
23. Friedland G, Andrews L, Schreibman T, et al. Lack of an effect of atazanavir on steady-tate pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS. 2005;19:1635-1641.
24. Ramanathan S, Wang H, Stondell T, et al. Pharmacokinetics and drug interaction profile of cobicistat boosted-elvitegravir with atazanavir, rosuvastatin, or rifabutin. Paper Presented at:13th International Workshop on Clinical Pharmacology of HIV Therapy; 2012; Barcelona, Spain. Vol O-03.
25. Fang WB, Chang Y, McCance-Katz EF, et al. Determination of naloxone and nornaloxone (noroxymorphone) by high-performance liquid chromatography- electrospray ionization- tandem mass spectrometry. J Anal Toxicol. 2009;33:409-417.
26. Bruce RD, Kresina TF, McCance-Katz EF. Medication-assisted treatment and HIV/AIDS:A spects in treating HIV-infected drug users. AIDS. 2010;24:331-340.